Patents by Inventor Christian Engwerda

Christian Engwerda has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180264091
    Abstract: Certain components of crude bromelain extract have surprisingly been found to not support, or to interfere with, the anti-inflammatory benefit of bromelain. By removing the detrimental components, the remaining component(s) have increased anti-inflammatory effectiveness.
    Type: Application
    Filed: August 18, 2016
    Publication date: September 20, 2018
    Inventors: Tracey L. Mynott, Christian Engwerda
  • Patent number: 9663777
    Abstract: The invention relates to a component of bromelain which is largely responsible for the ability of bromelain to interrupt the MAP kinase cascade. The component contains ananain and comosain and is useful in the treatment or prevention of diseases and conditions mediated by T cell activation or by activation of the MAP kinase pathway.
    Type: Grant
    Filed: October 12, 2010
    Date of Patent: May 30, 2017
    Assignee: Sarantis Pty Ltd
    Inventors: Tracey Lehanne Mynott, Christian Engwerda, Keith Peek
  • Publication number: 20110027259
    Abstract: The invention relates to a component of bromelain which is largely responsible for the ability of bromelain to interrupt the MAP kinase cascade. The component contains ananain and comosain and is useful in the treatment or prevention of diseases and conditions mediated by T cell activation or by activation of the MAP kinase pathway.
    Type: Application
    Filed: October 12, 2010
    Publication date: February 3, 2011
    Applicant: SARANTIS PTY LTD
    Inventors: Tracey Lehanne MYNOTT, Christian ENGWERDA, Keith PEEK
  • Patent number: 7833963
    Abstract: The invention relates to a component of bromelain which is largely responsible for the ability of bromelain to interrupt the MAP kinase cascade. The component contains ananain and comosain and is useful in the treatment or prevention of diseases and conditions mediated by T cell activation or by activation of the MAP kinase pathway.
    Type: Grant
    Filed: June 3, 2003
    Date of Patent: November 16, 2010
    Assignee: Sarantis Pty Ltd
    Inventors: Tracey L. Mynott, Christian Engwerda, Keith Peek
  • Publication number: 20040057948
    Abstract: The invention relates to a component of bromelain which is largely responsible for the ability of bromelain to interrupt the MAP kinase cascade. The component contains ananain and comosain and is useful in the treatment or prevention of diseases and conditions mediated by T cell activation or by activation of the MAP kinase pathway.
    Type: Application
    Filed: June 3, 2003
    Publication date: March 25, 2004
    Inventors: Tracey Lehanne Mynott, Christian Engwerda, Keith Peek
  • Publication number: 20020188107
    Abstract: A novel protein is a component of stem bromelain and is an anti-cancer agent, an immunostimulant and has antimicrobial activity. The protein may be isolated from stem bromelain by methods such as HPLC.
    Type: Application
    Filed: December 28, 2001
    Publication date: December 12, 2002
    Applicant: Provalis UK Limited
    Inventors: Tracey Lehanne Mynott, Christian Engwerda, Keith Peek
  • Publication number: 20020102253
    Abstract: The invention relates to a component of bromelain which is largely responsible for the ability of bromelain to interrupt the MAP kinase cascade. The component contains ananain and comosain and is useful in the treatment or prevention of diseases and conditions mediated by T cell activation or by activation of the MAP kinase pathway.
    Type: Application
    Filed: December 29, 2000
    Publication date: August 1, 2002
    Inventors: Tracey Lehanne Mynott, Christian Engwerda, Keith Peek
  • Patent number: 6335427
    Abstract: A novel protein is a component of stem bromelain and is an anti-cancer agent, an immunostimulant and has antimicrobial activity. The protein may be isolated from stem bromelain by methods such as HPLC and has a molecular weight of about 25.08 kDa and an isoelectric point of about 3.8 or 3.85.
    Type: Grant
    Filed: August 25, 1999
    Date of Patent: January 1, 2002
    Assignee: Provalis UK Limited
    Inventors: Tracey Lehanne Mynott, Christian Engwerda, Keith Peek